OneShield, a provider of insurance technology solutions for property and casualty insurers and managing general agents (MGAs) ...

Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as ...

Corvus Pharmaceuticals reported a net loss per share of $(0.10) for Q2 2025, a smaller loss than the analyst estimate of $(0.13). Research and development expenses rose sharply to $7.9 million, ...

OneShield, a leading provider of core insurance technology solutions for property and casualty insurers and MGAs, today ...